Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Plus Therapeutics, Inc. (PSTV : NSDQ)

• Company Description    Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics Inc., is based in Austin, Texas. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $0.45 Daily Weekly Monthly 20 Day Moving Average: 6,273,289 shares Shares Outstanding: 99.26 (millions) Market Capitalization: $44.40 (millions) Beta: 0.66 52 Week High: $2.31 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.50% -18.95% 12 Week 120.89% 100.65% Year To Date -61.10% -63.52%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2710 REED ROAD SUITE 160 - HOUSTON,TX 77051 USA ph: 737-255-7194 fax: 858-450-4335 investor@plustherapeutics.com http://www.plustherapeutics.com

• General Corporate Information    Officers Marc. H. Hedrick - Chief Executive Officer and President Richard J. Hawkins - Chairman Andrew Sims - Chief Financial Officer and VP of Finance An van Es-Johansson - Director Greg Petersen - Director Peer Information Plus Therapeutics, Inc. (GSAC) Plus Therapeutics, Inc. (CASI) Plus Therapeutics, Inc. (ALCD.) Plus Therapeutics, Inc. (OMNN) Plus Therapeutics, Inc. (CGPI.) Plus Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 72941H509 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 99.26 Most Recent Split Date: 5.00 (0.07:1) Beta: 0.66 Market Capitalization: $44.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: 0.84 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 13.59 Price/Cash Flow: - Price / Sales: 8.35 EPS Growth vs. Year Ago Period: 98.59% vs. Previous Quarter: 98.21% Sales Growth vs. Year Ago Period: 8.68% vs. Previous Quarter: 31.26% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -117.72 03/31/25 - -202.73 12/31/24 - -179.92 Current Ratio 06/30/25 - 1.26 03/31/25 - 1.03 12/31/24 - 0.34 Quick Ratio 06/30/25 - 1.26 03/31/25 - 1.03 12/31/24 - 0.34 Operating Margin 06/30/25 - -199.36 03/31/25 - -359.03 12/31/24 - -235.13 Net Margin 06/30/25 - -357.85 03/31/25 - -520.90 12/31/24 - -222.84 Pre-Tax Margin 06/30/25 - -357.85 03/31/25 - -520.90 12/31/24 - -222.84 Book Value 06/30/25 - 0.03 03/31/25 - -1.39 12/31/24 - -1.52 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - 0.00 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©